Breast magnetic resonance imaging (MRI) has become an essential component of breast imaging. Whether it is used as a problem-solving tool or a screening test or for staging patients with breast cancer, it detects many lesions in the breast. The challenge for the radiologist is to distinguish significant from insignificant lesions and to direct their management. A brief summary of the terminology according to the American College of Radiologists lexicon will be provided. This review article will cover the differential diagnosis of enhancing lesions, including masses and nonmass enhancement, from benign and malignant causes. Some of the specific morphologic and kinetic features that help to differentiate benign from malignant lesions will be illustrated, and positive predictive values of these features will be reviewed. The various methods of investigating enhancing lesions of the breast will be discussed, including second-look ultrasound, ultrasound-guided biopsy, stereotactic biopsy, and MRI-guided biopsy. A practical approach to the management of MRI-detected lesions will include timing of follow-up, when to biopsy and when to ignore enhancing lesions in the breast. R esum e L'imagerie par r esonance magn etique (IRM) mammaire est devenue une composante essentielle de la mammographie. Qu'elle serve d'outil de r esolution de probl emes, de d epistage ou de stadification du cancer du sein, l'IRM d etecte un grand nombre de l esions du sein. Pour les radiologistes, le d efi consiste a distinguer les l esions importantes des l esions frustes, et a orienter leur gestion en cons equence. Un sommaire de la terminologie inspir ee du lexique du American College of Radiologists est fourni. L'article porte sur le diagnostic diff erentiel des l esions prenant le contraste, incluant les rehaussements avec et sans masse, de causes b enignes a malignes. L'article pr esente certaines fonctions morphologiques et cin etiques qui facilitent la diff erenciation des l esions b enignes et malignes, en plus d'analyser leurs valeurs pr edictives positives. Les diverses m ethodes d'examen des l esions prenant le contraste sont abord ees, notamment l' echographie de second regard, la biopsie guid ee par ultrasons, la biopsie st er eotaxique et la biopsie guid ee par IRM. Une approche pratique de la gestion des l esions d etect ees par IRM doit d efinir quand proc eder aux examens de suivi et a une biopsie et quand ne pas tenir compte des l esions prenant le contraste dans le sein.
For a lesion to be identified on breast MRI, it must enhance. Contrast-enhanced breast MRI relies on tumour neo-angiogenesis, whereby tumours incite the formation of new vessels and proliferation of existing capillaries [1] . This neovascularization is faulty: there is increased capillary leakage because of large endothelial fenestrations, arteriovenous shunting, and perfusion of the capillary bed is poorly controlled by regular physiologic mechanisms. Identification of early enhancement of tumours secondary to their more rapid accumulation of contrast than surrounding tissue is the underlying principle of breast MRI, which allows for highly sensitive detection of invasive tumours. It is what distinguishes tumours from the more gradually enhancing glandular tissue. However, when hormonal stimulation is present, glandular tissue enhances more intensely and rapidly [2] . Therefore, the best method to minimize benign glandular enhancement is to image patients in week 2 (also called the postmenstrual phase) of the menstrual cycle, when hormonal stimulation is lowest. Kuhl et al [2] found a significant reduction in the number of enhancing lesions and the enhancing velocity in the second week of the menstrual cycle compared with the first, third, and fourth weeks (P > .001). They also demonstrated that more than 60 enhancing foci were present in 16 or 20 normal volunteers and that 73% of these foci resolved completely during follow-up [2] . The timing of the breast MRI in the second week of the menstrual cycle, therefore, is the single best method to minimize glandular enhancement and maximize detection of truly malignant lesions. The most marked glandular enhancement is seen in lactational women, who have significant hormonal stimulation, which can significantly impair sensitivity of the MRI (Figure 1 ).
Terminology
A standardized terminology was developed through the ACR lexicon [3] . A focus is defined as a punctate nonspecific area of enhancement and usually is less than 5 mm, too small to be further characterized ( Figure 2) . A focus has a small likelihood of malignancy; it was found to be less than 3% in 1 study [4] . A mass is a space-occupying lesion, which has a correlate on nonenhanced T1-and T2-weighted (W) images ( Figure 3 ). Nonmasslike enhancement (NME) is defined as an area, not a space-occupying mass, whose internal enhancement results in a pattern discrete from the surrounding parenchyma, often interspersed with fat or normal tissue (Figures 4 and 5) . No correlate is identified on noncontrast T1-and T2-W sequences. Kinetics refers to the plot of signal intensity (SI) of a lesion over time, after contrast injection. This is divided into the initial phase, which occurs in the first 2 minutes of the injection, and delayed phase, 2-10 minutes, which may be persistent (type I): progressive, continued increase in contrast enhancement over time (6% malignant) ( Figure 6 ); plateau (type II): the SI does not change over time, (64% malignant); and washout (type III), where SI decreases after peaking (87% malignant) ( Figure 3 ) [5] . When assessing the kinetics of a lesion, only the most suspicious enhancement should be reported, because there may be significant heterogeneity to the enhancement.
Benign Masses
Benign tumours enhance on breast MRI. They tend to enhance in a more gradual and less intense fashion than malignant tumours, but there is considerable overlap. Empiric measurements have been used, including maximum rate of enhancement (slope of enhancement uptake) and increase in signal intensity after contrast agent administration [2, 5e8] . Typically, benign lesions on breast MRI have a gradual enhancement pattern and smooth, wellcircumscribed margins [3] . The reader is referred to many comprehensive textbooks on this subject, because this review article cannot encompass the description of all benign lesions shown on MRI. The most common benign neoplasm of the breast is the fibroadenoma, which enhances to a variable extent on breast MRI. The enhancement curves are usually continuous or plateau. On noncontrast T2-W images, SI varies according to fluid content; more cellular and myxomatous lesions often seen in younger patients are high in signal, whereas less cellular and sclerotic lesions, seen in older patients, may have low or intermediate SI [9] . On T1 contrast-enhanced images, fibroadenomas are usually round, oval, or lobulated, with smooth, circumscribed margins. Cellular, myxomatous fibroadenomas show uniform and homogenous enhancement. Of enhancing fibroadenomas 40%-60% contain nonenhancing septations, which, if seen, are diagnostic with up to >95% certainty ( Figure 6 ) [10] . When there is no enhancement, there is an almost 100% certainty of benignity [9] . Papillomas are solitary or multiple: when solitary, they are typically located adjacent to the nipple-areolar complex and appear as enhancing, wellcircumscribed, subareolar masses, and 50% are associated with duct ectasia [9, 11, 12] ; when multiple, they tend to be more peripherally located and bilateral [9, 13] . Their enhancement pattern is usually gradual or plateau. Cysts are the most common lesion seen on MRI. They are well circumscribed, of high SI on T2-W images, low on T1-W images before contrast, unless there is high protein or blood content, when they may be of high SI on T1. Cysts do not enhance; however, when cysts are inflammatory, they will demonstrate rim enhancement of the cyst walls, which may be confused with the rim enhancement of a malignant tumour. A second-look ultrasound (US) will easily confirm their cystic nature. Biopsy cavities have inflammatory changes and may also simulate rim-enhancing lesions, but the history of recent biopsy or surgery is essential to avoid overcalling these lesions ( Figure 7 ). Figure 2 . Foci in a high-risk patient on annual screening magnetic resonance imaging (MRI). Axial subtracted gadolinium-enhanced image, demonstrating multiple small enhancing foci in both breasts; the most prominent is seen in the left lateral breast (arrow). All foci remained stable on MRI for several years. Fat necrosis is a common lesion seen on MRI, which occurs after loss of the vascular supply from surgery or trauma. The MRI appearance of fat necrosis is characteristic; it consists of a mass of low SI on T2-W, high signal on T1-W sequences without fat suppression, and low signal on T1-W with fat suppression. Rim enhancement of the fat is often identified and usually consists of a thin rim of enhancement, which corresponds pathologically to a giant cell granulomatous reaction [14] . The enhancement curves of the lesion may be deceptive and may demonstrate washout but are variable, with plateau and gradual curves also shown. Enhancing septations may also be shown ( Figure 8 ).
Lymph nodes are part of the normal anatomy of the breast. They are most commonly seen in the axilla and axillary tail but may be seen in other parts of the breast. Normal lymph nodes are classically identified by their high T2 signal, reniform shape, and well-circumscribed margins, with a fatty hilum (see Table 1 ). They may enhance markedly with contrast ( Figure 9 ). It is important to confirm that they are lymph nodes, if these features are not present, then Figure 5 . A 54-year-old woman, with biopsy-proven ductal carcinoma in situ (DCIS) in her left breast, who underwent preoperative breast magnetic resonance imaging, demonstrating nonmasslike enhancement in her left breast (long thin arrows) that extended from the chest wall to behind the nipple; a mammographically occult mass in the same breast (short thick arrow) in the retroareolar region; and multiple, enhancing foci in both breasts (white arrows). Left breast ultrasound-guided biopsy confirmed that the retroareolar left breast mass was a 1.2-cm invasive ductal cancer, and the foci in the left breast at mastectomy were benign proliferative changes, the extent of DCIS correlated with the nonmass enhancement. the enhancing lesions should be categorized as BI-RADS 3 (Breast Imaging Reporting and Data System), and followed up with MRI to avoid missing small enhancing cancers ( Figure 10 ). Abscess and mastitis will cause significant inflammation in the breast and enhance markedly with contrast. This may easily be confused with malignancy ( Figure 11 ). Pseudoangiomatous stromal hyperplasia may have a mass appearance and show enhancement on MRI [15, 16] .
For lesions with definitely benign features, such as fat necrosis in which the central fat is clearly identified, fibroadenomas with nonenhancing septations, classic lymph nodes, and inflammatory cysts, then the breast MRI can be classified as a BI-RADS 2, as one would for mammography and breast US, and no further follow-up would be required. If some features suggest a benign entity, but a definite benign diagnosis cannot be made, then a BI-RADS 3 classification would be assigned, and a follow-up MRI, usually in 6 months time would be recommended to confirm stability. Typical lesions that are called BI-RADS 3 are wellcircumscribed masses with gradual (type 1 curves) enhancement but with no nonenhancing septations, a solitary focus in a high-risk patient, and non-masslike enhancement that is likely glandular but found to be asymmetric. It is helpful to remember to correlate with prior mammograms and a second-look US in determining if the lesion remains BI-RADS 3; for example, a mammogram may demonstrate stable glandular tissue at a site of NME, which confirms that it is benign, and, in fact, BI-RADS 2. The assignment of a BI-RADS 3 lesion should be reserved for lesions with a high likelihood of benignity, with a less than 2% chance of malignancy, as with other breast imaging studies.
Malignant Masses
The most common invasive cancers manifest on MRI as enhancing masses, with spiculated, irregular, or lobulated margins. The internal enhancement is heterogenous and may demonstrate rim enhancement, a feature highly predictive of malignancy [10] . Cancers tend to have early rapid initial enhancement that peaks by 2-3 minutes and then plateau (type II curve) or washout (type III curve). On non-fatsuppressed T2-W images, breast cancers tend to be hypointense relative to glandular tissue, which may distinguish them from benign lesions that show ''malignant'' type enhancement, such as lymph nodes, typically high SI on T2-WI ( Figure 9 ) [1] .
Benign Non-masslike Enhancement
Nonproliferative fibrocystic changes, which are not associated with an increased risk of breast cancer, consist of cysts of varying sizes, stromal fibrosis, and apocrine metaplasia. Proliferative fibrocystic changes include hyperplasia without atypia, papillomas, and sclerosing adenosis. Atypical Table 1 Benign breast magnetic resonance imaging features Fatty hilum or fatty containing lesion Nonenhancing internal septations Rim-enhancing cyst hyperplasia (atypical lobular and atypical ductal hyperplasia) included in the spectrum of fibrocystic disease are associated with an increased risk of breast cancer [17] . All of these entities may be identified on MRI, usually as NME, and enhance to a variable extent. Sclerosing adenosis often shows patchy or diffuse NME [18] .
Malignant Non-masslike Enhancement
The 2 malignant diagnoses that may have NME are ductal carcinoma in situ (DCIS) and lobular carcinomas. A recent study demonstrated that DCIS is visualized by direct uptake of gadolinium within neoplastic mammary ducts, collecting within the ducts [19] , in comparison with invasive tumours, which depend on tumour angiogenesis. This direct , in a high-risk patient, presumed to be a benign lymph node. However, the margins are slightly irregular, and the lesion was not seen on T2 WI, nor was a definite fatty hilum seen. The patient presented 9 months later with a new mammographic finding at the same location. (B) Repeated magnetic resonance imaging, demonstrating enlargement of the lesion with poorly defined margins (arrow); stereotactic biopsy diagnosed a small invasive ductal carcinoma. visualization allows for good demonstration of the extent of DCIS. It has been shown that higher-grade DCIS is more likely to enhance on MRI, whereas lower-grade DCIS is not always visualized [20] . Results of several studies demonstrated an increased sensitivity of MRI when compared with mammography for detection of DCIS [20e23]. In 1 study, of 167 women with a final surgical pathology diagnosis of pure DCIS, who had undergone both MRI and mammography, 93 of these cases (56%) were diagnosed by mammography and 153 by MRI (92%) (P < .0001). Of the 89 high-grade DCIS, 43 (48%) were missed by mammography but were diagnosed by MRI alone; all 43 cases missed by mammography were detected by MRI [20] .
Lobular cancers grow by a diffuse growth pattern (linear infiltrating pattern of growth) and may not have a mass appearance. These infiltrating cells may be fed by means of diffusion of pre-existing fibroglandular capillaries, which is why they may demonstrate weak angiogenic activity and may show a more ''benign'' enhancement pattern ( Figure 12 ). One should not rely on kinetics for nonmass enhancement: although some malignant lesions will demonstrate type II and III curves, many will not.
The distribution of NME is important and can be compared with the distribution of calcifications in mammography. A segmental or regional distribution of NME should raise suspicions for malignancy, just as it would with this pattern with calcifications. Similarly, linear or ductal enhancement is concerning for DCIS. In this regard, sagittal images and reconstructed maximum intensity projection images are very helpful to assess the extent of enhancement. Any asymmetric pattern of enhancement should be considered worthy of investigation (Figure 12 ), first by correlating with the mammogram, because it may correspond to a new cluster of calcifications, or an asymmetric density. If a mammographic correlate is identified, then a stereotactic biopsy should be performed. If no mammographic correlate is found, then a second-look US should be obtained. If a sonographic correlate is identified, then an US-guided biopsy should be done. If there is no sonographic correlate found, then an MRI-guided breast biopsy must be performed.
Computer-Aided Detection
Computer-aided detection (CAD) programs have been introduced into clinical practice to help discriminate between benign and malignant lesions, and help improve specificity of breast MRI. They are being increasingly used in clinical practice [24, 25] . CAD programs for breast MRI provide automated lesion kinetic information. In 1 study, of 154 consecutive lesions (41 malignant, 113 benign) in 125 women, false-positive rates were reduced by 23.0% at the 100% enhancement threshold (P ¼ .02) when compared with the initial interpretation of radiologists [25] . In another study, of 125 lesions (42 malignant and 83 benign), no significant differences in the initial phase of enhancement were detected, but a significant difference in delayed kinetics categorized by most suspicious enhancement types was found (P ¼ .0005) [26] . The best CAD parameters to distinguish benign from malignant lesions have not yet been established, but these studies point to the improved specificity of breast MRI with the use of CAD. Practically, CAD provides a visual map to demonstrate the most suspicious enhancement and may be particularly helpful in a patient with multiple enhancing lesions. With 1 image, the most suspicious lesions may be clearly identified, which permits easier determination of the need for subsequent management (Figure 13 ). This will usually include further evaluation with MRI-directed US and biopsy. The use of CAD, therefore, may improve efficiency of reading breast MRIs and reduce the number of false-positive results.
Overall Assessment
The positive predictive values (PPV) for MRI-detected lesions are reported in the order of 25%, with a range of 15%-40% [27, 28] . A recent meta-analysis of 19 studies showed that PPV ranged from 19%-100% for detection of multifocal and multicentric disease [29] . For evaluation of contralateral disease in patients with recently diagnosed breast cancer, the PPV of MRI is 25% [30] . In women who are at high risk, the PPVs are higher: 35%-64% [31, 32] .
In multivariate analysis of combinations of features, masses of 1 cm or larger with heterogeneous enhancement and irregular margins had a 68% probability of malignancy [33] . Masses of 1 cm or larger, with smooth margins and homogeneous enhancement, had the lowest predicted probability of malignancy, of 3% [33] . In a study of 100 consecutive patients with MRI-guided biopsy, overall PPV for MRI-detected lesions was 25%, with carcinoma found in 15 of 60 masses (25%) vs 10 of 40 nonmass lesions (25%); most malignant masses (73%) were infiltrating carcinoma, whereas most malignant nonmass lesions (90%) were DCIS [34] . The features with the highest PPV were spiculated margin (80% carcinoma), rim enhancement (40%), and irregular shape (32%) for mass lesions and segmental (67%) or clumped linear and ductal enhancement (31%) for nonmass lesions (see Table 2 ) [34] . In this same study, visually assessed kinetic patterns were not significant predictors of carcinoma, but washout was present in 70% of infiltrating carcinomas vs 9% of DCIS lesions (P < .01) [34] . Carcinoma was present in 17 of 88 lesions (19%) classified as suspicious vs 8 of 12 lesions (67%) classified as highly suggestive of malignancy (P ¼ .001) [34] . In another study, ductal enhancement accounted for 21% of MRI-detected lesions that had biopsy and had a PPV of 26% [18] . Combinations of BI-RADS lesion descriptors can predict the probability of malignancy for breast MRI masses but not for NME. A study of 258 lesions in 196 women showed that BI-RADS descriptors and size were not predictors of malignancy in NME [33] . Further research focused on predictive features of NME is needed.
Biopsy of MRI-Detected Lesions
When an enhancing lesion is identified on the MRI, the first job of the radiologist is to determine if it looks benign. If no definite features of a benign lesion are present, then a definite diagnosis must be obtained, usually with imageguided biopsy. Once a lesion is identified as suspicious or not definitely benign, the radiologist must investigate further, with the help of other breast imaging. The first step is to correlate with the most recent mammograms, preferably within the past 6 months of the breast MRI. If the enhancing MRI lesion is identified on the mammogram and appears definitely benign, for example, lymph node or fat necrosis, then no further investigation is required. If the lesion is seen on the mammogram and is not definitely benign, then a stereotactic biopsy may be performed. In some cases, MRI lesions may correspond to asymmetric densities or masses on the mammogram and can be successfully targeted for stereotactic biopsy (Figure 14) .
All patients should have a recent mammogram available to correlate with the breast MRI. In the high-risk screening population, annual breast MRIs are obtained at the same time as an annual mammogram or are staggered at 6-month intervals. The mammograms should be available at the time of the breast MRI reporting to allow for immediate correlation of the MRI with the mammogram, which is useful to demonstrate a benign intramammary lymph node or to show a stable enhancing mass on serial mammograms of a benign lesion. Having the mammogram available also allows for correlation in case of biopsy; if the enhancing lesion corresponds to a mammographic finding it allows for stereotactic guidance (Figure 14) .
If the lesion is not seen on the mammogram, then the next step is to perform a ''second-look'' US. The term second-look US is commonly used, but other terms that may be more appropriate are ''targeted ultrasound,'' or MRI-directed ultrasound.'' An MRI-directed US allows greater characterization of the lesion and may diagnose a definitely benign lesion, such as a benign intramammary lymph node, inflammatory cyst, or fibroadenoma, or may serve to identify the suspicious lesion and provide the target for US-guided biopsy. It is always easier, cheaper, and more comfortable for the patient to perform an US-guided biopsy if a sonographic correlate is identified. More than 50% of suspicious enhancing lesions on MRI are seen with targeted ''secondlook'' US [35, 36] . It is important to emphasize to referring physicians and patients that a ''second-look'' US is a targeted breast US directed to the MRI abnormality and may yield new findings, regardless of whether the patient underwent a breast US before the MRI was performed, because this area may not have been imaged on the first breast US. If the enhancing lesion is a mass, then the likelihood of it being detected is about 65% and is even higher (85%) if the lesion is malignant [35, 36] . Even a 6-mm mass may be clearly identified with targeted US (Figure 15 ). Conversely, if the lesion consists of NME, then the likelihood of it being identified with US is much lower, in the range of 11%-31% [35e37]. Size matters, and the larger the lesions, the more likely they are to be seen at ''second-look'' US. In 1 study, of 202 lesions, 63% of masses 5-10 mm, 71% of masses 11-20 mm, and 88% of masses larger than 21 mm had sonographic correlates; for nonmass lesions, no cases of NME smaller than 20 mm were found sonographically, whereas 22% of NME > 21 mm had an US correlate [35] . In another recent study, of 519 suspicious MRI-detected lesions in 361 women, 13% of NME 6-10 mm in size, 25% of 11-15 mm NME lesions, and 42% NME >15 mm were seen with second-look US [36] . Interestingly, in this study, BI-RADS 5 lesions were much more likely to be seen with US than BI-RADS 4 lesions: for NME, 75% BI-RADS 5 vs 26% BI-RADS 4 lesions were identified with US, whereas for masses 81% vs 59% were seen [36] . For clumped NME, 84% had a sonographic correlate, compared with only 16% of nonclumped NME [36] . Thus, increasing size of the lesion, increased level of suspicion, and clumped NME are all features that help predict whether the secondlook US will be positive.
The malignant lesions with successful sonographic correlation tend to present with subtle sonographic findings [35] . The second-look US should use landmarks to identify the area, such as the distance from the nipple, distance from the chest wall, location, that is, for example, o'clock or quadrant. A careful second-look US by a radiologist familiar with breast MRI is critical to the success of the study. A feature of malignant-enhancing masses on second-look US is that the masses may often not demonstrate suspicious or typical malignant features, as defined by the Stavros criteria [38] . For example, in a recent study, of 158 consecutive patients with 202 suspicious enhancing breast lesions, 33% of lesions seen sonographically did not demonstrate any suspicious features [35] . The only findings were poorly circumscribed margins and increased vascularity, secondary features of malignancy. The radiologist performing the second-look US, therefore, must have a high level of suspicion when evaluating US of an enhancing mass and should proceed to biopsy even when definite suspicious features are not present (Figure 15 ).
Any suspicious mass seen on US requires further evaluation with US-guided biopsy to confirm malignancy and avoid overcalling cancer. NME that is seen on US also requires US-guided biopsy to confirm or exclude malignancy, with US-guided biopsy (Figure 16 ). When assessing the breast MRI, to avoid unnecessary delay in surgery, only lesions likely to be seen on second-look US should be targeted. In our experience and as supported by the literature, NME lesions smaller than 10 mm have a low likelihood of sonographic correlate (0%-13%) [35, 36] and may not warrant the time or expense of looking. If the small NME lesions are still suspicious, then it is probably advisable to proceed directly to MRI-guided breast biopsy ( Figure 17 ).
US-Guided Breast Biopsy
If a suspicious enhancing lesion is identified with targeted US, every attempt should be made to proceed immediately with biopsy. It is inadvisable to have the patient return for a third visit, where another radiologist may not identify the same lesion or have the same level of suspicion as the original reporting radiologist. At our institution, we allow for extra time to perform the US-guided biopsy at the time of the second-look US, if needed. This is most efficient and accurate, and most convenient for the patient. When the lesion is larger than 5 mm, a 14-gauge biopsy needle is used to obtain the tissue with a minimum of 3 cores. However, if the lesion is smaller than 5 mm or consists of a very subtle hypoechoic area, then it may be advisable to proceed to vacuum-assisted biopsy, to avoid underestimation of the lesion [39] . At our institution, we use 14-gauge needles for most sonographic findings and reserve the vacuum-assisted biopsies for those lesions smaller than 5 mm, when the lesion may be completely removed by the biopsy and requires clip placement for localization. A clip should also be placed if there is any uncertainty about the accuracy of the sonographic correlate, and allows for correlation with the MRI after the procedure [36] .
MRI-Guided Breast Biopsy
Results of several studies have shown that masses that are seen on second-look US are more likely to be malignant than masses that are not seen with US. In 1 study, of 64 patients with 93 suspicious, nonpalpable, mammographically occult lesions evident on MRIs and recommended for biopsy, for which directed US assessment was performed, the likelihood of carcinoma was significantly higher among lesions with an US correlate (43% carcinomas) than lesions without an US correlate (14% carcinomas) (P ¼ .01) [37] . However, this study highlights that, even when a lesion is not seen with second-look US, there is still a significant chance that it could be malignant. Results of other studies have shown that the incidence of breast cancer in sonographically occult enhancing MRI lesions is in the range of 25% in MRI biopsy series [27, 28] . To perform an MRI breast biopsy, the reader is referred to another recent article in CARJ by Price and Morris [40] . The main risk of breast MRI is of overcalling enhancing lesions. Simply recommending surgery for enhancing lesions may lead to unnecessary surgery, such as mastectomy. It is imperative that a tissue diagnosis be obtained when leading to a change in surgical management.
When to Follow up or Ignore MRI-Detected Lesions
Not all MRI lesions can be classified as definitely benign or malignant. A small percentage of these lesions are classified as ''probably benign,'' or BI-RADS 3. The reported range is 10%-24% of breast MRIs [41e45]. Although accumulated experience with mammography has resulted in a goal of <2% cancer for mammographic lesions classified as BI-RADS 3, the rate of malignancy for MRI-equivalent BI-RADS 3 lesions has yet to be established [46] . A study in 2005 evaluated 79 of 473 women (17%) with probably benign MRI lesions in whom 2-year radiographic and clinical follow-up was available. In this group, 4 women (6%) were diagnosed with breast cancer between 14 and 18 months after the initial MRI [41] . Liberman et al [43] published their experience of 89 patients with BI-RADS 3 lesions of a total of 367 patients (24%). They found malignancies in 9 women, 5 with DCIS and 4 with invasive cancer, for a total of 10% with malignancy. In their study, the median follow-up was 9 months (range, 1-18 months), and biopsy was precipitated mainly by progression on follow-up MRI [43] . In this study, a large number (24%) were classified as BI-RADS 3, and very likely the BI-RADS 3 rate of malignancy was high given that the population studied was predominantly high risk. Two more recent studies have shown that less common use of BI-RADS 3 (10%) resulted in a much lower rate of malignancy, of 0.9% [44, 45] . Careful use of BI-RADS 3, therefore, is strongly recommended, particularly in high-risk patients, in whom any enhancing lesion should be treated with suspicion.
The criteria for probably benign mammographic lesions may not apply to MRI. In patients with solitary, smooth, MRIdetected masses referred for biopsy in prior studies, the frequency of malignancy was 17%-44% [34, 47] . To date, a subset of MRI-detected lesions that have less than a 2% chance of being malignant have not been identified [43] . However, foci with 100% persistent enhancement have all been shown to be benign on follow-up [44] . Probably, in patients undergoing staging MRI with known cancer, an ipsilateral enhancing lesion smaller than 4 mm will likely be treated by breast radiation and can be safely ignored [48] . Conversely, a 4mm focus in a high-risk patient undergoing screening should be followed up, particularly when it is the only lesion in the breast, because it may prove significant ( Figure 9 ).
Pitfalls in Analysis of Breast MRIs
Probably the greatest concern of referring physicians is the false-positive rate of breast MRIs. Overcalling a false positive on a breast MRI may lead to unnecessary surgery, such as mastectomy, when a simple lumpectomy would Figure 18 . Algorithm for management of a breast magnetic resonance imaging (MRI)-detected lesion. BIRADS ¼ Breast Imaging Reporting and Data System; f-u ¼ follow-up; MR ¼ magnetic resonance; US ¼ ultrasound. Table 3 Principles of breast MRI reporting Be specific, if the lesion looks typically benign, BI-RADS 2 If the lesion is probably benign but not confirmed on second-look US, then the follow-up with breast MRI in 6 months, BI-RADS 3. If the lesion disappears on follow-up, then return to normal. If the lesion persists, unchanged, then it is unclear for how long it should be followed up, probably for 2 years. If the lesion is suspicious, recommend biopsy, directed by correlation with mammogram and second-look US; perform MRI-guided biopsy if no correlate is found, BI-RADS 4 or 5 Have the mammogram available at the time of the breast MRI reporting and correlate with MRI findings Expedite the ''second-look'' US and biopsy: no more than 7 days after the MRI if possible Communicate the findings to the referring surgeon effectively, eg, level of confidence, next step in management BI-RADS ¼ Breast Imaging Reporting and Data System; MRI ¼ magnetic resonance imaging; US ¼ ultrasound.
suffice, or surgery for a benign lesion. The simplest way to have the referring physician lose confidence in breast MRI is to have a patient undergo unnecessary surgery. It, therefore, is imperative to confirm with biopsy that disease is present, whenever possible. In our practice, we routinely obtain an MRI biopsy when a positive result will cause a change in patient management. Our practice audit indicates that approximately 7% of all breast MRIs result in an MRI biopsy.
Some principles in the management of breast MRI lesions are: (1) be as definite and specific as possible; (2) for definitely benign lesions, avoid biopsy or follow-up; (3) do not assume a suspicious enhancing lesion is malignant; if it will result in a change in surgical management, then biopsy is required for confirmation; and (4) avoid delays in surgery as much as possible (see Table 3 ). It is important that reporting radiologists are familiar with the next step of management: breast MRIs should be read by radiologists who are comfortable with recommendations for breast biopsies. As with other breast imaging, a BI-RADS category should be assigned to every breast MRI report. This allows for standardization of the reporting and effective communication of the degree of suspicion of the MRI findings, with a recommendation for further management. BI-RADS provides a standard language that can be used to compare findings across multiple scientific studies and enables all radiologists to describe mammographic findings in a consistent manner [3] . If a lesion is suspicious on MRI, a BI-RADS category 4 or 5 should be assigned, because a biopsy will be performed. Further imaging with a second-look US or mammogram is simply obtained to determine the best technique for imageguided biopsy (Figure 18 ).
In summary, there are some practical approaches to the management of MRI-detected lesions, which can be followed by most radiologists. Use of the ACR MRI lexicon and BI-RADS categories standardizes reports and directs management that is consistent and easy to communicate. Approximately 25% of breast MRI lesions are positive for cancer, at least 50% of suspicious enhancing lesions are identified on second-look US and mammograms, whereas about 20% lesions require follow-up. A small number of patients, less than 10%, will require MRI breast biopsy for diagnosis.
